REVIEW ARTICLE

CrossMark

Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases

Zhonglin Cai[1] · Jianzhong Zhang[1] · Hongjun Li[1]

Abstract

Patients with cardiovascular disease (CVD) frequently have erectile dysfunction (ED) because the two conditions have similar risk factors and potential mechanisms. The therapeutic effect of CVD is strongly dependent upon long-term management of the condition. Patients with CVD tend to have poor medication compliance, and the coexistence of ED often discourages patients with CVD from continuing their long-term CVD management, thus worsening CVD treatment compliance. The two major reasons for poor compliance are that (i) the adverse effects of cardiovascular medications on erectile function drive people to reduce the prescribed dosage or even stop taking the medications to obtain satisfactory sexual arousal and (ii) a worsening mental state due to ED reduces medication compliance. The regular administration of phosphodiesterase-5 inhibitors (PDE5is) guarantees that the prescribed medication dosages are easy to comply with and that they improve the mental status of patients by enhancing their erectile function, resulting in improved long-term management of CVD through medication compliance. PDE5is themselves also play a role in reducing cardiovascular events and improving the prognosis. We recommend prescribing PDE5is for ED and suggest that PDE5i administration is a promising strategy to improve the long-term management of patients with both ED and CVD.

Keywords Cardiovascular disease · Erectile dysfunction · Long-term management · Medication compliance · Phosphodiesterase-5 inhibitor

Introduction

Erectile dysfunction (ED) is defined as the inability of the penis to become erect or maintain sufficient erection rigidity to accomplish satisfactory sexual activity [1]. ED is a common type of sexual dysfunction that significantly influences quality of life. Cardiovascular disease (CVD), such as coronary disease, hypertension, and hyperlipidemia, has risk factors similar to those of ED, including aging, lipid metabolism disorders, obesity, and smoking [2, 3]. Therefore, ED often occurs concurrently with CVD [4]. Accumulating evidence shows that ED, as an independent risk factor, predicts the risk of CVD [5–7]. Many experimental and clinical studies have demonstrated that phosphodiesterase-5 inhibitors (PDE5is) have protective effects against cardiovascular problems such as heart failure (HF), myocardial infarction (MI), and pulmonary arterial hypertension (PAH) [8–12]. PDE5i administration may be an ideal treatment strategy for male patients with both ED and CVD.

Relationship Between ED and CVD

ED as a Predictor of CVD

The symptoms of CVD in patients with both CVD and ED are more serious than those in patients with CVD alone [13], and the severity of ED is positively associated with CVD [6]. Additionally, patients with ED have a higher risk of ischemic cardiac disease, HF, and peripheral vascular disease than those

✉ Hongjun Li
  lihongjun@pumch.cn

  Zhonglin Cai
  714833558@qq.com

  Jianzhong Zhang
  15895827758@163.com

[1] Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China

without ED [13]. Hippisley-Cox et al. developed updated QRISK3 risk prediction models and concluded that the presence of ED helps to identify patients most at risk for heart disease and stroke [14]. Therefore, ED can be used as an independent risk factor to predict the risk of CVD and cardiovascular events [6, 15]. A reduction in erectile hardness is also closely related to the risk of cardiovascular events, and severely low erectile hardness is associated with a greatly increased risk of cardiovascular events [16]. The relationship between erection rigidity and CVD risk directly demonstrates the relationship between ED and CVD. Finally, in a comparison of ED and the prognosis of CVD, a negative association has been observed between the effort capacity in patients with post-acute MI and the presence and degree of ED [17]. Overall, evidence of the relationships among ED, CVD, and the prognosis of CVD indicates that ED indirectly reflects the severity of CVD and is a predictor of CVD.

ED Reduces the Frequency of Sexual Intercourse, Resulting in an Increased Risk of CVD

A sexual intercourse frequency of four or more times per month is associated with a lower risk of CVD compared with a sexual intercourse frequency of fewer than once per month [6]. Hall et al. reported that a sexual intercourse frequency of once or less than once per month is related to an increased risk of CVD compared with a sexual intercourse frequency of two to three times per week. Additionally, the association with the frequency of sexual intercourse was still present after adjusting for the impact of ED [18]. According to these results, a lower frequency of sexual intercourse increases the risk of CVD and is an independent risk factor. Therefore, patients with ED who have a lower frequency of sexual intercourse also have an increased risk of CVD.

Regular Use of PDE5is for ED and CVD

Reduction of CVD Risk by Administration of PDE5is

One study showed that patients who were treated with a PDE5i for ED had lower mortality and a lower risk of hospitalization for HF compared with those who were not treated for ED [19]. Many experimental studies have shown that PDE5is are cardioprotective, particularly for HF and MI [10, 20–24]. A clinical trial regarding the direct effect of PDE5is on MI demonstrated that the use of a PDE5i is associated with a lower risk of overall mortality and mortality in those with a history of acute MI [25]. Studies of PDE5is and mortality in men with type 2 diabetes, which is closely associated with the prevalence of CVD, have also shown that PDE5i use is independently associated with decreased mortality in patients

with type 2 diabetes, suggesting independence of the PDE5i effect on mortality[26, 27]. These findings indicate that the decreased risk of CVD and the improved CVD prognosis in patients treated with PDE5is for ED is primarily due to the cardiovascular protection provided by PDE5is [19, 26, 27].

Protective Mechanisms of PDE5is on CVD

PDE5 is expressed in vascular smooth muscle cells, cardiac myocytes, and platelets as well as in the penile vasculature [28]. Under pathological conditions, PDE5 expression is significantly elevated in cardiovascular tissues, such as the myocardial cells of HF tissues [29]. PDE5i treatment has positive effects on most CVDs, such as thrombus-related CVD, HF, MI, and PAH [8–12, 30, 31]. The protective mechanism of PDE5is on CVD is closely related to the cGMP/protein kinase G (PKG) and cAMP/protein kinase A pathways [32] (Fig. 1).

PDE5is, Platelets, and Thrombi

Fibrinogen, Ca^{2+}, and glycoprotein IIb/IIIa are the three most important factors involved in the aggregation of platelets. The intracellular calcium (Ca^{2+}) level is down-regulated by nitric oxide and/or the PDE5i-mediated cGMP-PKG signaling pathway in platelets, which functions through phosphorylation of G protein 18, inositol 1,4,5-triphosphate (IP3) receptor 1 channel, and IP3 receptor-associated cGK I substrate protein [33]. All of these participate in regulation of the intracellular Ca^{2+} level [33]. cGMP-PKG signaling phosphorylates Rap1, thus suppressing activation of glycoprotein IIb/IIIa by inhibiting small GTPase signaling [34]. The changes in the Ca^{2+} level and activation of glycoprotein IIb/IIIa inhibit the activation and aggregation of platelets [34]. P-selectin expression and RhoA activation are also inhibited by PKG, inhibiting the shape change in platelets and the formation of platelet-leukocyte complexes, which adhere to endothelial cells [35, 36]. Additionally, elevated cGMP competes with phosphodiesterase3 (PDE3), which hydrolysates cAMP, and increases cAMP by binding to the PDE3-binding site of cAMP [32, 37]. Protein kinase A is activated by elevated cAMP and is involved in inhibiting the change in the platelet shape induced by thrombin via phosphorylation of a vasodilator-stimulated phosphoprotein [37].

PDE5i, Cardiomyocytes, and HF

The onset of heart failure is typically preceded by cardiac hypertrophy and/or cardiac remodeling [38]. The cGMP/PKG pathway induced by PDE5is inhibits cardiac remodeling by inhibiting the activity of calcineurin or reducing the

Fig. 1 NO, catalyzed and synthesized by nitric oxide synthase, activates GC, which changes GTP into cGMP activating PKG; AC that is activated by adrenaline changes ATP into cAMP, which activates PKA. PDE5 hydrolyzes cCGMP into 5′-GMP, and PDE3 hydrolyzes cAMP into 5′-AMP. PDE5i inhibits PDE5, whose hydrolyzation is inhibited and promotes the expression of e/i NOS. Finally, the expression levels of cGMP and PKG are increased. cGMP can bind to the PDE3-binding site of cAMP, and then, PDE3 hydrolyzation of cAMP is inhibited. Lastly, the expression levels of cAMP and PKA are increased. Both PKG and PKA have the positive roles in the cardiovascular protection including the inhibition of thrombus formation, improvement of myocardial infarction and heart failure, reduction of pulmonary arterial hypertension, and so on. NO nitric oxide, NOS nitric oxide synthase, GC guanosine cyclase, AC adenylate cyclase, cGMP cyclic guanosine monophosphate, cAMP cyclic adenosine monophosphate, PDE phosphodiesterase, GTP guanosine triphosphate, ATP adenosine triphosphate, PKA protein kinase A, PKG protein kinase G

expression of brain natriuretic peptide by phosphorylating extracellular regulated kinase (ERK) [10]. Additionally, PKG causes a decrease in the influx of Ca^{2+} by phosphorylating the transient receptor potential canonical channel and subsequently decreasing calcineurin activity, leading to reduced dephosphorylation of nuclear factor of activated T cells, which promotes cardiac hypertrophy in an active state [39]. The RhoA/Rho-kinase pathway and regulator of G protein signaling 2 (RGS2) are also inhibited by the cGMP/PKG pathway, resulting in improved cardiac hypertrophy [29, 40, 41]. Furthermore, PKG induced by PDE5is phosphorylates titin to enhance diastolic compliance and cardiac troponin I to reduce Ca^{2+} sensitivity of the myofilaments [32]. PDE5is may be associated with anti-apoptosis in cardiomyocytes through an increase in the Bcl-2-to-Bax ratio or reduced endoplasmic reticulum stress [42–44]; antiinflammation through Gq signaling regulatory action by inhibiting RGS2, RGS3, or RGS4 [45]; and fibrosis by inhibiting transforming growth factor-β [21, 46] to improve HF via the cGMP/PKG pathway.

PDE5is, Cardiomyocytes, and MI

The area of an MI is dependent on cardiomyocyte apoptosis, and mitochondria are key in determining the MI area [11]. PDE5is reduce the mitochondrial area and ameliorate the adhesion force of the mitochondrial surfaces [11]. The molecular mechanism of PDE5is in MI involves the $mitoK_{ATP}$ and mitochondrial Ca^{2+}-sensitive potassium channels (BK), both of which are activated by the cGMP/PKG pathway (Fig. 2) [12, 47]. BK knockout in cardiomyocytes causes higher serum levels of cardiac troponin I as a marker of MI [12]. PKG induced by PDE5is via elevated cGMP decreases Ca^{2+} influx by inhibiting BK, subsequent amounts of reactive oxygen species, and phosphorylated ERK/AKT levels, resulting in apoptosis of cardiomyocytes [12, 48, 49]. PKG phosphorylates ERK1/2 and glycogen synthase kinase 3 beta and, with the help of increased Bcl-2, subsequently opens $mitoK_{ATP}$ channels, preserves ATP, and decreases Ca^{2+} influx in the mitochondria by inhibiting the mitochondrial permeability transition pore [47].

Fig. 2 Normally, after an ischemic episode during MI, the reperfusion damage of cardiomyocytes is associated with open mPTP in mitochondria, which induce a collapse of the mitochondrial membrane potential, ATP depletion, and cell death. Having closed mPTPs is essential to cell survival after reperfusion in MI. Whether the mPTP is opened or closed depends on BK and mitoK$_{ATP}$ of mitochondria. First, PKG induced by PDE5i is beneficial for opening the BK channel and, thereby, causes the K$^+$ influx, decreased Ca^{2+}, and the phosphorylation of RISK pathway-related molecules, e.g., ERK1/2 and Akt. The K$^+$ influx causes the high mitochondrial matrix K$^+$ content and provokes the uncoupling of the ETC, thereby resulting in low amounts of ROS. Phosphorylated ERK1/2 and Akt activate downstream molecules, e.g., GSK-3β. Low amounts of ROS, decreased Ca^{2+}, and molecules downstream of the RISK pathway inhibit the opening of the mPTP. Second, PKG causes phosphorylation of ERK1/2 and GSK3β and increases the expression of Bcl-2. The increased Bcl-2-to-Bax ratio prevents the cardiomyocyte apoptosis. With the help of Bcl-2, phosphorylated GSK3β opens mitoK$_{ATP}$ and causes K$^+$ influx, which results in decreased Ca^{2+}. Decreased Ca^{2+} is also not beneficial to the openness of the mPTP. Finally, the openness of the mPTP is restricted, resulting in the maintenance of the mitochondrial membrane potential, preserving ATP, promoting cell survival, and reducing the myocardial infarction areas. MI myocardial infarction, mPTP mitochondrial permeability transition pore, ATP adenosine triphosphate, BK Ca^{2+}-activated K$^+$ channels of the BK type, mitoK$_{ATP}$ mitochondrial ATP-dependent K$^+$ channels, PKG protein kinase G, ERK extracellular regulated protein kinases, Akt protein kinase B, GSK-3β glycogen synthase kinase-3β, ROS reactive oxygen species, Bcl-2 B cell lymphoma-2

PDE5is, Pulmonary Vascular Smooth Muscle Cells, and PAH

The pulmonary artery pressure is closely related to the vascular smooth muscle, where PDE5is increases cGMP expression and activates PKG by inhibiting PDE5, resulting in the dilation of vascular smooth muscle cells [50, 51]. The balance between proliferation and apoptosis of pulmonary vascular smooth muscle cells (PVSMCs) is associated with pulmonary vascular remodeling, which can increase pulmonary artery pressure [52, 53]. Ca^{2+} is essential in the reduced proliferation and enhanced apoptosis of PVSMCs, and the cGMP/PKG pathway induced by PDE5is is activated by PKG downstream proteins such as mitogen-activated protein kinase phosphatase-1 and peroxisome proliferator-activated receptor gamma [54–56]. The transient receptor potential canonical gene, which encodes a related protein on the store-operated Ca^{2+} channel that is activated by the Ca^{2+} store depletion, is then inhibited, and capacitive Ca^{2+} entry via this channel is reduced, resulting in decreased intracellular levels of Ca^{2+} [55, 56]. The low level of Ca^{2+} affects transcription factors associated with the expression of proliferation-related genes and inhibits the proliferation of PVSMCs [56, 57]. Additionally, the low level of Ca^{2+} relieves the inhibition of Ca^{2+} for phosphorylating Smad, which is a nuclear transcription factor that promotes the expression of pro-apoptosis genes and enhances apoptosis of PVSMCs [57].

The PDE5i Strategy for Patients with Both ED and CVD

The PDE5i medication dosing protocols for treatment of ED include once daily (taking the medicine once daily) and on demand (taking the medicine some time before sexual activity) [58]. Some patients following the on-demand PDE5i protocol for ED have a poor response to PDE5is. This occurs because ED is often caused by dysfunction of the vascular endothelium, which is closely related to CVD [59–61]. Compared with on-demand treatment, once-daily treatment has a higher therapeutic effect in terms of the International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP) and is safe and generally well tolerated [62–64]. The once-daily protocol improves vascular endothelial function and has positive effects on ED [60, 65–67], which may be due to cumulative drug effectiveness [68, 69]. One study on the effect of 5-mg once-daily versus 5-mg alternate-day tadalafil for ED revealed no significant differences in the therapeutic effects as measured by the IIEF, International Prostate Symptom Score, and SEP-Q3 between the two groups [70]. The abovementioned results suggest that the cumulative effect of regular PDE5i administration is closely associated with the therapeutic effects and that the frequency of PDE5i administration is not limited to once daily. Additionally, compelling clinical evidence demonstrates that therapeutic effects can be obtained by regular dosing of a PDE5i, such as 10-mg vardenafil twice daily [71] or 50-mg sildenafil twice daily [72] for Raynaud's disease or 40-mg sildenafil three times daily [73], 5-mg vardenafil twice daily [74], or 40 mg/day tadalafil [75] for PAH. Therefore, regular, chronic administration of a PDE5i at a fixed frequency and prescribed dose may be suitable for patients with ED and CVD.

PDE5is can cause adverse effects such as vasodilatation, facial flushing, and an accelerated heart rate [32]. However, the adverse effects are moderate, transient, and reversible, and they gradually disappear over the course of administration [32]. The regular PDE5i treatment dose for ED and CVD is the therapeutic dose or the lowest recommended dose, which does not cause remarkable adverse effects and is well tolerated by patients [76]. Additionally, cumulative evidence shows that PDE5is combined with anti-CVD drugs, including diuretics, β-blockers, α1-blockers, angiotensin-converting enzyme inhibitors, and Ca^{2+} channel blockers, have no obvious adverse effects; the only exception is nitrate ester medications [77, 78]. However, it is safe to administer nitrates 24 h after using either sildenafil or vardenafil and 48 h after using tadalafil [79, 80]. Interestingly, some cardiovascular medications have synergistic actions with PDE5is. Atorvastatin enhances the response to sidenafil in patients with hypercholesterolemia and improves the curative effect of PDE5is [81]. The combination of fasudil with sidenafil had synergistic effects on animal models of PAH and in clinical trials, where it improved exercise capacity and reduced hospitalization rates [82, 83]. The combination of diltiazem and tadalafil attenuates ischemia reperfusion injury [84]. Hence, regular use of a PDE5i for ED and CVD is safe, effective, and feasible.

Regular Use of PDE5is Improves Treatment Adherence in Patients with ED and Concomitant CVD

Poor adherence reduces the CVD treatment effects, accelerates the progression of the disease, and increases the incidence rate, risk of complications, and healthcare costs [85]. A study of acute ischemic stroke and statins showed that the risk of recurrent stroke increases with reduced adherence to treatment after adjusting for related factors [86]. Another clinical study also demonstrated that good adherence to statin medication results in a lower relative risk of adverse cardiovascular events than poor adherence in discharged patients with acute coronary syndrome [87]. Interestingly, the protective effects of good adherence between different statin dose groups are similar [87]. Reduced adherence increases not only the disease burden but also the total medical care expenses and is negatively correlated with medical care costs [88].

ED is a common complication of CVD but can also be caused by some anti-CVD drugs, such as peripheral

sympatholytics and central sympatholytics, diuretics, β-blockers, and aldosterone antagonists, which negatively affect sexual activity [89–91]. Patients with medication-treated CVD might adjust the dose and frequency of the medication or even discontinue the drug without permission to reduce the adverse effects on erectile function and obtain a satisfactory sexual life [92]. This is the primary reason why ED decreases medication compliance in patients with CVD. ED, which causes lower erection rigidity, has negative effects on self-esteem, self-confidence, and mood [93, 94]. In one epidemiological study, subjects with ED had significantly lower scores on self-confidence and self-esteem scales than non-ED subjects, and there was an increased incidence of depressive symptoms in patients with ED [95, 96]. Negative spirituality, such as reduced self-confidence, frustrated self-esteem, anxiety, and annoyance, which directly affect the motivation of patients to chronically manage CVD and adhere to anti-CVD medication, results in reduced therapeutic effects [97–99]. This is another reason why ED reduces the compliance of CVD treatment for patients with both ED and CVD.

Compliance with PDE5is is positively associated with an increased frequency of sexual activity and improved erection hardness [100]. PDE5is have high treatment success rates for ED and allow patients to achieve satisfactory sexual activity [101]. Recent meta-analyses have shown IIEF-EF, which reflects overall erectile function, and SEP3, which reflects erectile function sufficient for successful intercourse, superiority with once-daily tadalafil, which more patients prefer [102, 103]. Thus, regular use of a PDE5i for patients with both ED and CVD not only improves compliance but also prevents patients from discontinuing the prescribed anti-CVD medication to achieve satisfactory sexual activity, resulting in further improved compliance. Finally, psychology is an important factor that can affect adherence to CVD medication and their therapeutic effects on CVD [104]. Treating ED with a PDE5i improves self-confidence and self-esteem [105, 106]; thus, PDE5is serve as psychological supportive therapy to improve compliance. Overall, PDE5is may be candidate medications for both CVD and ED to improve therapeutic effects and decrease total medical care expenses through better treatment adherence.

Prospects

CVD is a chronic disease in men of advanced age and is frequently accompanied by ED. As a predictor of CVD, ED can be used to foretell the severity of CVD and the risk of cardiovascular events. Regular use of a PDE5i for ED and CVD achieves optimal effectiveness to improve vascular endothelial function, enhanced erectile function and cardiovascular protection, and improved compliance to medications. PDE5is consequently may play a role reducing cardiovascular

events and improving the prognosis of CVD. Interestingly, prostate tissue expresses PDE5, which helps to regulate the dynamic activity of smooth muscle in the transitional zone and secretory function and the proliferation of tissue in the prostate [107]. PDE5is have positive therapeutic effects on benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) and have been approved for the treatment of BPH/LUTS [108, 109]. BPH/LUTS is believed to be one of the most common comorbidities of ED, and the association between ED and BPH/LUTS becomes stronger with age [110–112]. The concurrence of BPH/LUTS and ED is believed to be associated with the metabolic syndrome, which is characterized by multiple metabolic disorders including obesity, hyperglycemia, hypertension, and dyslipidemia [113]. These metabolic disorders, which are the pathological basis of CVD and diabetes mellitus, cause oxidation and degradation of the soluble guanylate cyclase (sGC) and reduced cyclic GMP (cGMP) levels. This results in LUTS and ED through strong contraction of smooth muscle in the prostate and penile cavernous body via a weakened NO-sGC-cGMP signaling pathway [114]. Thus, a close relationship exists among ED, CVD, and BPH/LUTS, and PDE5 is the common target. In addition, while the PDE5is may be ideal candidate medications for both ED and CVD, PDE5i administration is most likely to be an important future direction for treating older patients with simultaneous ED, CVD, and BPH/LUTS and decreasing medical care costs because these diseases are common and have huge health economic impacts on men of advanced age.

dysfunction; *GPCR*, G protein–coupled receptor; *HF*, Heart failure; *IIEF*, International Index of Erectile Function; *IP3*, Inositol 1,4,5-triphosphate; *MI*, Myocardial infarction; *MKP-1*, Mitogen-activated protein kinase phosphatase-1; *PAH*, Pulmonary arterial hypertension; *PDE5i*, PDE5 inhibitors; *PDE3*, Phosphodiesterase3; *PKG*, Protein kinase G; *PPARγ*, Peroxisome proliferator-activated receptor gamma; *PVSM*, Pulmonary vascular smooth muscle; *Rap1*, Ras-related protein 1; *SEP*, Sexual encounter profile; *SOC*, Store-operated Ca^{2+} channel; *TRPC*, Transient receptor potential canonical

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. McMahon CG. Erectile dysfunction. Intern Med J. 2014;44(1): 18–26.
2. Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820–7.
3. Imprialos KP, Stavropoulos K, Doumas M, et al. Sexual dysfunction, cardiovascular risk and effects of pharmacotherapy. Curr Vasc Pharmacol. 2018;16(2):130–42.
4. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99–109.
5. Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis. Circulation. 2018, pii: CIRCULATIONAHA.118.033990.
6. Ho CH, Wu CC, Chen KC, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male. 2016;19(2): 96–101.
7. Turek SJ, Hastings SM, Sun JK, et al. Sexual dysfunction as a marker of cardiovascular disease in males with 50 or more years of type 1 diabetes. Diabetes Care. 2013;36(10):3222–6.
8. Hwang IC, Kim YJ, Park JB, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17(1):150.
9. Mátyás C, Németh BT, Oláh A, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur J Heart Fail. 2017;19(3):326–36.
10. Imai Y, Kariya T, Iwakiri M, et al. Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. PLoS One. 2018;13(4):e0195528.
11. Lee KH, Kwon SJ, Woo JS, et al. Effects of sildenafil on nanostructural and nanomechanical changes in mitochondria in an ischaemia-reperfusion rat model. Clin Exp Pharmacol Physiol. 2014;41(10):763–8.
12. Frankenreiter S, Bednarczyk P, Kniess A, et al. cGMP-elevating compounds and ischemic conditioning provide cardioprotection against ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation. 2017;136(24):2337–55.
13. Banks E, Joshy G, Abhayaratna WP, et al. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. PLoS Med. 2013;10(1):e1001372.
14. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.
15. Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014;127(3):174–82.
16. Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res. 2008;20(1):92–9.
17. Compostella L, Compostella C, Truong LV, et al. History of erectile dysfunction as a predictor of poor physical performance after an acute myocardial infarction. Eur J Prev Cardiol. 2017;24(5): 460–7.
18. Hall SA, Shackelton R, Rosen RC, et al. Sexual activity, erectile dysfunction, and incident cardiovascular events. Am J Cardiol. 2010;105(2):192–7.
19. Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103(16): 1264–70.
20. Tobler D, Bouchardy J, Reto E, et al. Effect of phosphodiesterase-5 inhibition with tadalafil on systemic right ventricular size and function—a multi-center, double-blind, randomized, placebo-controlled clinical trial—serve trial—rational and design. Int J Cardiol. 2017;243:354–9.
21. Westermann D, Becher PM, Lindner D, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107(6):308.
22. Wang JS, Kovanecz I, Vernet D, et al. Effects of sildenafil and/or muscle derived stem cells on myocardial infarction. J Transl Med. 2012;10:159.
23. Lee TM, Chen CC, Chung TH, et al. Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. Eur J Pharmacol. 2012;690(1–3):124–32.
24. Mennander AA, Vuohelainen V, Aanismaa RS, et al. Sildenafil after cardiac arrest and infarction; an experimental rat model. Scand Cardiovasc J Suppl. 2013;47(1):58–64.
25. Anderson SG, Hutchings DC, Woodward M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750–6.
26. Hackett G, Jones PW, Strange RC, et al. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes. 2017;8(3):104–11.
27. Hackett G, Heald AH, Sinclair A, et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Prxzact. 2016;70(3):244–53.
28. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C–12C.
29. Chau VQ, Salloum FN, Hoke NN, et al. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300(6):H2272–9.
30. De Bon E, Bonanni G, Saggiorato G, et al. Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. Angiology. 2010;61(6): 602–6.
31. Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40(7):1232–40.

32. Hutchings DC, Anderson SG, Caldwell JL, et al. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018. pii: heartjnl-2017-312865.

33. Wilson LS, Elbatarny HS, Crawley SW, et al. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S A. 2008;105(36):13650–5.

34. Makhoul S, Walter E, Pagel O, et al. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. Nitric Oxide. 2018;76:71–80.

35. Bodie SL, Ford I, Greaves M, et al. Thrombin-induced activation of RhoA in platelet shape change. Biochem Biophys Res Commun. 2001;287(1):71–6.

36. Libersan D, Rousseau G, Merhi Y. Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets. Thromb Haemost. 2003;89(2):310–7.

37. Jensen BO, Selheim F, Døskeland SO, et al. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood. 2004;104(9):2775–82.

38. Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401–38.

39. Koitabashi N, Aiba T, Hesketh GG, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010;48(4):713–24.

40. Takimoto E, Koitabashi N, Hsu S, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2):408–20.

41. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25(9):1767–75.

42. Salloum FN, Chau VQ, Hoke NN, et al. Tadalafil prevents acute heart failure with reduced ejection fraction in mice. Cardiovasc Drugs Ther. 2014;28(6):493–500.

43. Li N, Yuan Y, Li S, et al. PDE5 inhibitors protect against post-infarction heart failure. Front Biosci (Landmark Ed). 2016;21: 1194–210.

44. Gong W, Duan Q, Cai Z, et al. Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. Br J Pharmacol. 2013;170(7):1396–409.

45. Corinaldesi C, Di Luigi L, Lenzi A, et al. Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. J Endocrinol Investig. 2016;39(2):143–51.

46. Gong W, Yan M, Chen J, et al. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling. Front Med. 2014;8(4):445–55.

47. Kukreja RC, Salloum FN, Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol. 2012;59(22):1921–7.

48. Frankenreiter S, Groneberg D, Kuret A, et al. Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase. Cardiovasc Res. 2018;114(6):822–9.

49. Behmenburg F, Dorsch M, Huhn R, et al. Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats. PLoS One. 2015;10(12): e0144737.

50. Francis SH, Busch JL. Corbin JD, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525–63.

51. Gao Y. Conventional and unconventional mechanisms for soluble guanylyl cyclase signaling. J Cardiovasc Pharmacol. 2016;67(5): 367–72.

52. Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;j5492:360.

53. Yamamura A, Fujitomi E, Ohara N, et al. Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 down-regulation in idiopathic pulmonary arterial hypertension in vitro. Eur J Pharmacol. 2017;810:44–50.

54. Li B, Yang L, Shen J, et al. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg. 2007;105(4):1034–41 table of contents.

55. Wang J, Yang K, Xu L, et al. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis. Am J Respir Cell Mol Biol. 2013;49(2):231–40.

56. Wang C, Wang J, Zhao L, et al. Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry. J Pharmacol Sci. 2008;108(1):71–8.

57. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S20–31.

58. Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010;4:159–71.

59. Lane-Cordova AD, Kershaw K, Liu K, et al. Association between cardiovascular health and endothelial function with future erectile dysfunction: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2017;30(8):815–21.

60. Özdabakoğlu O, Güllülü S, Sağ S, et al. Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil. Int J Impot Res. 2017;29(3):96–100.

61. Kempler P, Amarenco G, Freeman R, et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev. 2011;27(7): 665–77.

62. Qiu S, Tang Z, Deng L, et al. Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. Sci Rep. 2016;6:32853.

63. Javaroni V, Queiroz Miguez M, Burla A, et al. Response to on-demand vardenafil was improved by its daily usage in hypertensive men. Urology. 2012;80(4):858–64.

64. Kim E, Seftel A, Goldfischer E, et al. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2015;31(2):379–89.

65. Hackett G, Krychman M, Baldwin D, et al. Coronary heart disease, diabetes, and sexuality in men. J Sex Med. 2016;13(6):887–904.

66. Kratz MT, Schirmer SH, Baumhäkel M, et al. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism. Atherosclerosis. 2016;251:291–8.

67. Pernow J, Jung C. The emerging role of arginase in endothelial dysfunction in diabetes. Curr Vasc Pharmacol. 2016;14(2):155–62.

68. Jamshidian H, Borhan A, Kooraki S, et al. Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect? J Pak Med Assoc. 2012;62(11):1195–8.

69. Ilic D, Hindson B, Duchesne G, et al. A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve

erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol. 2013;57(1):81–8.

70. Choi H, Kim JH, Shim JS, et al. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res. 2015;27(1):33–7.

71. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterasetype 5 inhibition is a novel therapeutic option in Raynaud's disease. Arch Intern Med. 2006;166:231–3.

72. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in thetreatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980–5.

73. Rubin LJ, Badesch DB, Flemming TR, et al. Long-term treatmentwith sildenafil citrate in pulmonary arterial hypertension. TheSUPER-2 Study. Chest. 2011;140:1274–83.

74. Jing ZC, Shen JY, Wu BX, et al. Vardenafil for the treatment ofpulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;183:1723–9.

75. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy inpulmonary arterial hypertension 2009;119:2894–903.

76. Sung HH, Lee SW. Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. Korean J Urol. 2012;53(6):377–85.

77. Nera A. Erectile dysfunction and cardiovascular disease: efficacyand safety of phosphodiesterase type 5 inhibitors in men with bothcondtions. Mayo Clin Proc. 2009;84:139–48.

78. Oliver JJ, Dear JW, Webb DJ. Clinical potential of combinedorganic nitrate and phosphodiesterase type 5 inhibitor in treatmentresistant hypertension. Hypertension. 2010;56:62–7.

79. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110:3149–55.

80. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005;96(12B):42M–6M.

81. Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010;22(1):51–60.

82. Zhang Y, Wu S. Effects of fasudil on pulmonary hypertension in clinical practice. Pulm Pharmacol Ther. 2017;46:54–63. https://doi.org/10.1016/j.pupt.2017.08.002.

83. Elias-Al-Mamun M, Satoh K, Tanaka S, et al. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circ J. 2014;78(4):967–76.

84. El-Sisi AE, Sokar SS, Abu-Risha SE, et al. Combination of tadalafil and diltiazem attenuatesrenal ischemia reperfusion-induced acute renal failure in rats. Biomed Pharmacother. 2016;84:861–9.

85. Zullig LL, Ramos K3, Bosworth HB. Improving medication adherence in coronary heart disease. Curr Cardiol Rep. 2017;19(11):113.

86. Kim J, Lee HS, Nam CM, et al. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. 2017;48(10):2723–30.

87. Xie G, Sun Y, Myint PK, et al. Six-month adherence to statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis. 2017;16(1):155.

88. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005 Jun;43(6):521–30.

89. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl. 1997;1:47–51.

90. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.

91. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:27–31.

92. Voils CI, Sandelowski M, Dahm P, et al. Selective adherence to antihypertensive medications as a patient-driven means to preserving sexual potency. Patient Prefer Adherence. 2008;2:201–6.

93. Kimura M, Shimura S, Tai T, et al. A web-based survey of erection hardness score and its relationship to aging, sexual behavior, confidence, and risk factors in Japan. Sex Med. 2013;1(2):76–86.

94. Intili H, Nier D. Self-esteem and depression in men who present with erectile dysfunction. Urol Nurs. 1998;18:185–7.

95. Martin-Morales A, Meijide Rico F, Garcia Gonzalez JI, et al. Psychological impact of erectile dysfunction on self-esteem and self-confidence. Actas Urol Esp. 2005;29:493–8.

96. Shabsigh R, Klein LT, Seidman S, et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52:848–52.

97. Hare DL, Toukhsati SR, Johansson P, et al. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365–72.

98. Ju A, Hanson CS, Banks E, et al. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract. 2018;68(671):e408–19.

99. Janssen-Niemeijer AJ, Visse M, Van Leeuwen R, et al. The role of spirituality in lifestyle changing among patients with chronic cardiovascular diseases: a literature review of qualitative studies. J Relig Health. 2017;56(4):1460–77.

100. Mazzola CR, Deveci S, Teloken P, et al. Exploring the association between erectile rigidity and treatment adherence with sildenafil. J Sex Med. 2013;10(7):1861–6.

101. Smith WB 2nd, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67(8):768–80.

102. Peng Z, Yang L, Dong Q, et al. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: a systematic review and meta-analyses. Urol Int. 2017;99(3):343–52.

103. Bansal UK, Jones C, Fuller TW, et al. The efficacy of tadalafil daily vs on demand in the treatment of erectile dysfunction: a systematic review and meta-analysis. Urology. 2018;112:6–11.

104. Bosworth HB, Blalock DV, Hoyle RH, et al. The role of psychological science in efforts to improve cardiovascular medication adherence. Am Psychol. 2018;73(8):968–80.

105. Costa P, Grandmottet G, Mai HD, et al. Impact of a first treatment with phosphodiesterase inhibitors on men and partners' quality of sexual life: results of a prospective study in primary care. J Sex Med. 2013;10(7):1850–60.

106. Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731–40.

107. Tinel H, Stelte-Ludwig B, Hütter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006;98(6):1259–63.

108. Brousil P, Shabbir M, Zacharakis E, et al. PDE-5 inhibitors for BPH-associated LUTS. Curr Drug Targets. 2015;16(11):1180–6.

109. Cellek S, Cameron NE, Cotter MA, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11(4):231–41.

110. Seftel AD, de la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67(1):32–45.

111. Korneyev IA, Alexeeva TA, Al-Shukri SH, et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74–9.

112. Song J, Shao Q, Tian Y, et al. Lower urinary tract symptoms, erectile dysfunction, and their correlation in men aged 50 years and above: a cross-sectional survey in Beijing, China. Med Sci Monit. 2014;20:2806–10.

113. Gacci M, Carini M, Salvi M, et al. Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging. 2014;31(6):425–39.

114. Mónica FZ, Antunes E. Stimulators and activators of soluble guanylate cyclase for urogenital disorders. Nat Rev Urol. 2018;15(1):42–54.